Abstract
We sought to determine the hepatic fibrosis-reversal effects upon simultaneous administration of lithospermate B (LAB), an anti-oxidant, and nivocasan, a caspase inhibitor, to rats compared with each compound alone. Liver fibrosis was induced in Sprague–Dawley rats by thioacetamide (TAA). Rats were treated with TAA and then given LAB and (or) nivocasan. Fibrotic areas were evaluated quantitatively by computerized morphometry. Apoptosis was assessed using a TUNEL assay, and immunohistochemical staining for malondialdehyde (MDA) and 4-hydroxy-2-nonenal (4HNE) was performed to assess oxidative stress levels. Real-time quantitative PCR was used to quantify expression of fibrosis-related genes. The degree of hepatic fibrosis was significantly reduced in rats treated with LAB and nivocasan compared to either treatment alone (P < 0.001). Treatment with each compound significantly decreased expression of fibrosis-related genes, such as type I collagen α1 (col1α1), α-SMA and TGF-β1 (P < 0.05). Co-treatment with LAB and nivocasan further reduced col1α1 expression compared to treatment with either compound. A TUNEL assay revealed that hepatocyte apoptosis was significantly decreased in the group treated with nivocasan compared to other groups (P < 0.01). Immunohistochemistry showed a decrease in MDA and 4HNE, reflecting amelioration of oxidative stress, when LAB or LAB+nivocasan was administered compared to nivocasan alone (P < 0.01). Nivocasan was found to inhibit caspase-1, -3, -7, -9 and gliotoxin-induced death of rat-derived hepatic stellate cells was inhibited by nivocasan administration without overexpression of α-SMA. Conclusions: Co-incidental administration of LAB and nivocasan suppressed oxidative stress and apoptosis, resulting in enhanced reversal of hepatic fibrosis in rat.
Similar content being viewed by others
References
Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134:1655–1669
Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218
Ellis RE, Yuan JY, Horvitz HR (1991) Mechanisms and functions of cell death. Annu Rev Cell Biol 7:663–698
Reed JC, Tomaselli KJ (2000) Drug discovery opportunities from apoptosis research. Curr Opin Biotechnol 11:586–592
Nicholson DW (2000) From bench to clinic with apoptosis-based therapeutic agents. Nature 407:810–816
Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1:111–121
MacBride CB, McPhail LT, Steeves JD (1999) Emerging therapeutic targets in caspase-dependent disease. Emerg Ther Targets 3:391–411
Patel T (2000) Apoptosis in hepatic pathophysiology. Clin Liver Dis 4:295–317
Thorburn A (2004) Death receptor-induced cell killing. Cell Signal 16:139–144
Parola M, Robino G (2001) Oxidative stress-related molecules and liver fibrosis. J Hepatol 35:297–306
Koek GH, Liedorp PR, Bast A (2011) The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 412:1297–1305
Nieto N, Greenwel P, Friedman SL, Zhang F, Dannenberg AJ, Cederbaum AI (2000) Ethanol and arachidonic acid increase alpha 2(I) collagen expression in rat hepatic stellate cells overexpressing cytochrome P450 2EI. Role of H2O2 and cyclooxygenase-2. J Bio Chem 275:20136–20145
Kim KM, Kim YM, Park M, Park K, Chang HK, Park TK et al (2000) A broad-spectrum caspase inhibitor blocks concanavalin A-induced hepatitis in mice. Clin Immunol 97:221–233
Paik YH, Yoon YJ, Lee HC, Jung MK, Kang SH, Chung SI et al (2011) Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. Exp Mol Med 43:341–349
Jung M, Lee HC, Ahn CW, Park W, Choi S, Kim H et al (2002) Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. Chem Pharm Bull 50:1135–1136
Malekzadeh R, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat S, Tavangar SM et al (2004) Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2:344–347
Pockros PJ (2009) Antifibrotics for chronic hepatitis C. Clin Liver Dis 13:365–373
Liaw YF (2011) Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int 31(Suppl 1):117–121
Guicciardi ME, Gores GJ (2005) Apoptosis: a mechanism of acute and chronic liver injury. Gut 54:1024–1033
Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P et al (2010) Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 53:542–550
Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH et al (2007) Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46:324–329
DeMinicis S, Seki E, Oesterreicher C, Schnable B, Schwabe RF, Brenner DA (2008) Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cell (HSC). Hepatology 48:2016–2026
Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N et al (2012) A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 55:419–428
Hsu YC, Lin YL, Chiu YT, Shiao MS, Lee CY, Huang YT (2005) Antifibrotic effects of Salvia miltiorrhiza on dimethylnitrosamine-intoxicated rats. J Biomed Sci 12:185–195
Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ (2002) Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123:1323–1330
Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J et al (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9:347–351
Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ (2004) The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 308:1191–1196
Strobel Swanson L, Korsmeyer S, Cannistra SA (1996) BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 93:14094–14099
Masuoka HC, Guicciardi ME, Gores GJ (2009) Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis 13:467–475
Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K et al (2002) Prevention of hepatocellular carcinoma development associated with chronic hepatitis B by anti-fas ligand antibody therapy. J Exp Med 196:1105–1111
MacDonald GA, Bridle KR, Ward PJ, Walker NI, Houglum K, George DK et al (2001) Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominantly in acinar zone 3. J Gastroenterol Hepatol 16:599–606
Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA et al (2006) Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 43:435–443
Jiang JX, Mikami K, Venugopal S, Li Y, Torok NJ (2009) Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol 51:139–148
Nieto N, Greenwel P, Friedman SL, Zhang F, Dannenberg AJ, Cederbaum AI (2000) Ethanol and arachidonic acid increase alpha 2(I) collagen expression in rat hepatic stellate cells overexpressing cytochrome P450 2E1. Role of H2O2 and cyclooxygenase-2. J Biol Chem 275:20136–20145
Gu K, Zhao JD, Ren ZG, Ma NY, Lai ST, Wang J et al (2011) A natural process of cirrhosis resolution and deceleration of liver regeneration after thioacetamide withdrawal in a rat model. Mol Biol Rep 38:1687–1696
Acknowledgments
This study was funded in part by a Korea Healthcare Technology R&D Project from the Ministry for Health and Welfare, Republic of Korea (HI10C2020), and supported in part by a faculty research grant of Yonsei University College of Medicine for 2010 (6-2010-0032).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Do Young Kim and Sook In Chung contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kim, D.Y., Chung, S.I., Ro, S.W. et al. Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis 18, 1481–1491 (2013). https://doi.org/10.1007/s10495-013-0896-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10495-013-0896-5